Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care



Rating:

Share or cite this content

Citations should be made in the following way:
B. Sczepanski, S. Winterkamp, M. Boensch, I. Heinzelmann, K. Kenn (Schoenau, Germany). Is pulmonary rehabilitation (PR) an effective therapy in lymphangioleiomyomatosis (LAM)?. Eur Respir J 2012; 40: Suppl. 56, 1903

Member's Comments

No comment yet.

Related content which might interest you: Is pulmonary rehabilitation (PRP) effective in restrictive lung disease (RLD)? Source: Eur Respir J 2004; 24: Suppl. 48, 667s Year: 2004 Treatment of idiopathic pulmonary fibrosis (IPF) with nintedanib: an experience from the compassionate use program (CUP) in Estonia Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 The experience of use plasmaferesis in complex treatment in patients with pulmonary sarcoidosis (PS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Early-onset therapy with sirolimus helps to improve prognosis of patients with lymphangioleiomyomatosis (LAM) Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Impact of bisphosphonate (BP) use on lung function decline and treatment response in patients (pts) with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Effects of a combination of pulmonary rehabilitation (PR) and non invasive ventilation (NIV) in patients with advanced interstitial lung disease (ILD) Source: Annual Congress 2009 - Noninvasive ventilation in chronic respiratory failure Year: 2009 The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 72s Year: 2006 Differences in pulmonary function tests (PFTs) in patients with pulmonary lymphangioleiomyomatosis (LAM) and multiple benign pulmonary leiomyomatosis (MPL) Source: Eur Respir J 2004; 24: Suppl. 48, 222s Year: 2004 Does disease affect outcome of pulmonary rehabilitation (PR)? Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 Combined collapse therapy in the treatment of cavitary pulmonary tuberculosis (CPTB) Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Is occupational therapy (OT) really needed in pulmonary rehabilitation programmes (PRP)? Source: Eur Respir J 2005; 26: Suppl. 49, 529s Year: 2005 Treatment patients with pulmonary tuberculosis (PT) and accompanying pathologies by DOTS strategy Source: Eur Respir J 2005; 26: Suppl. 49, 192s Year: 2005 Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004 Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS) Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Pseudoneutropenia in lymphangioleiomyomatosis (LAM) patients receiving sirolimus: evaluation in a 100 patient cohort Source: ERJ Open Res, 4 (1) 00121-2017; 10.1183/23120541.00121-2017 Year: 2018 Is Pulmonary Rehabilitation (PR) effective in people recovering from severe COVID-19 (C-19) pneumonia? Source: Virtual Congress 2021 – Insights into rehabilitation and physiotherapy in COVID-19 Year: 2021 Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Experience with lung transplantation in lymphangioleiomyomatosis (LAM) in our center Source: Annual Congress 2008 - Donor organs and complications after lung transplantation Year: 2008